Serologicals announced that Chemicon International, its wholly-owned subsidiary based in Temecula, CA, has launched a new proprietary Amplifluor ID Pan-Enterovirus detection reagent
This product rapidly detects Pan-Enterovirus.
This is the first of many infectious disease detection products to be offered utilizing Chemicon's patented fluorescent detection technology, Amplifluor.
Enteroviruses cause a wide variety of disease ranging from polio, meningitis-encephalitis, myocarditis, hand-foot-and-mouth disease, conjunctivitis, and numerous other syndromes associated with intestinal organs.
Chemicon's Amplifluor ID Pan-Enterovirus Detection Reagent provides a sensitive, specific and rapid real-time method detection of enteroviruses.
The patented real-time Amplifluor fluorescent detection system is a powerful and flexible platform that can be utilized for a variety of nucleic acid amplification techniques.
Amplifluor can be incorporated into a wide array of analytical applications appropriate to HTS in drug discovery with other applications in genomics, clinical diagnostics, forensics, biothreat and food testing.
In addition, Amplifluor has been successfully used with strand displacement amplification, nucleic acid sequence-based amplification, and cascade rolling-circle amplification techniques.
Chemicon currently has several other viral detection targets in development leveraging the Amplifluor technology platform: Hepatitis B, Parvovirus B19, Babesia, Erhlichia, Lyme Disease, Influenza A and B, Herpes Simplex Viruses 1 and 2, and West Nile.
This patented platform technology allows for rapid real-time testing.
